> Details

Meister, Michael T.; Voss, Sandra; Schwabe, Dirk

Treatment of EBV‐associated nodular sclerosing Hodgkin lymphoma in a patient with ataxia telangiectasia with brentuximab vedotin and reduced COPP plus rituximab

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Treatment of EBV‐associated nodular sclerosing Hodgkin lymphoma in a patient with ataxia telangiectasia with brentuximab vedotin and reduced COPP plus rituximab
  • Contributor: Meister, Michael T.; Voss, Sandra; Schwabe, Dirk
  • imprint: Wiley, 2015
  • Published in: Pediatric Blood & Cancer
  • Language: English
  • DOI: 10.1002/pbc.25621
  • ISSN: 1545-5009; 1545-5017
  • Keywords: Oncology ; Hematology ; Pediatrics, Perinatology and Child Health
  • Origination:
  • Footnote:
  • Description: <jats:sec><jats:label /><jats:p>Patients with ataxia telangiectasia (AT) with malignancies face poor prognosis due to increased treatment‐related toxicity. Here, we report a 14‐year‐old male with AT and Hodgkin lymphoma (HL) who received brentuximab vedotin and reduced COPP plus rituximab courses. This treatment resulted in complete remission and showed no severe toxicity. Pediatr Blood Cancer © 2015 Wiley Periodicals, Inc.</jats:p></jats:sec>